COLOPLAST A/S |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 859.4 DKK | -1.92% |
|
+2.63% | +11.32% |
| 05-15 | COLOPLAST : Multiple silver linings in spite of a soft Q2 24 |  |
| 05-07 | European shares hit one-month high as earnings take centre stage | RE |
| Sales 2024 * | 27.04B 3.92B 5.38B | Sales 2025 * | 29.41B 4.26B 5.85B | Capitalization | 193B 28.01B 38.43B |
|---|---|---|---|---|---|
| Net income 2024 * | 5.24B 760M 1.04B | Net income 2025 * | 6.12B 887M 1.22B | EV / Sales 2024 * | 7.86 x |
| Net Debt 2024 * | 19.4B 2.81B 3.86B | Net Debt 2025 * | 17.9B 2.59B 3.56B | EV / Sales 2025 * | 7.18 x |
| P/E ratio 2024 * |
37
x | P/E ratio 2025 * |
31.6
x | Employees | 15,930 |
| Yield 2024 * |
2.36% | Yield 2025 * |
2.57% | Free-Float | 58.44% |
More Fundamentals
* Assessed data
More news
Latest transcript on Coloplast A/S
More press releases
| 1 day | -1.92% | ||
| 1 week | +2.63% | ||
| Current month | +1.54% | ||
| 1 month | -4.60% | ||
| 3 months | -4.95% | ||
| 6 months | +11.47% | ||
| Current year | +11.32% |
1 week
838.20
881.00
1 month
804.00929.20
Current year
757.80977.60
1 year
689.20977.60
3 years
689.201 194.00
5 years
689.201 194.00
10 years
413.101 194.00
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 54 | 07-12-31 | |
| Director of Finance/CFO | 52 | 05-12-31 | |
| Chairman | 65 | 87-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 76 | 68-09-30 | |
Carsten Hellmann
BRD | Director/Board Member | 60 | 17-11-30 |
| Chairman | 65 | 87-12-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 1.81% | 200 M€ | +18.96% | ||
| 1.11% | 253 M€ | +6.93% | ||
| 0.96% | 48 M€ | +10.03% | ||
| 0.85% | 3 M€ | +9.95% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-23 | 859.4 | -1.92% | 167,941 |
| 24-05-22 | 876.2 | +2.50% | 282,147 |
| 24-05-21 | 854.8 | +0.56% | 181,870 |
| 24-05-17 | 850 | +1.07% | 245,570 |
| 24-05-16 | 841 | +0.43% | 162,677 |
Delayed Quote Nasdaq Copenhagen, May 23, 2024 at 10:59 am
More quotes
Coloplast A/S specializes in the design, manufacturing, and marketing of disposable medical products. Net sales break down by family of products as follows:
- hygiene products (43.4%): urine bags, plugs, urinary testing systems and sets, etc.;
- ostomy care products (36.8%): bags and equipment used following intestinal operations;
- wound care and skincare products (11.9%): wound dressings, bandages, creams and gels;
- voice and respiratory care products (7.9%): voice prostheses for speaking, adhesives, laryngectomy cannulas for breathing, hands-free speaking devices, etc.
Net sales are distributed geographically as follows: Denmark (1.4%), the United States (21%), the United Kingdom (14%), France (10.8%) and other (52.8%).
Calendar
2024-06-06
- Investor Meeting
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
20
Last Close Price
859.4
DKK
Average target price
912.3
DKK
Spread / Average Target
+6.15%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +11.32% | 28.61B | |
| -32.33% | 3.02B | |
| +28.89% | 2.61B | |
| -19.22% | 2.49B | |
| +3.12% | 2.19B | |
| +34.44% | 2.03B | |
| -7.25% | 1.98B | |
| +25.74% | 1.33B | |
| +31.35% | 1.33B | |
| -1.73% | 1.27B |
- Stock Market
- Equities
- COLO B Stock
